CIK 0001557746 · Non-accelerated filer<br>Smaller reporting company
Aclaris Therapeutics, Inc.
Sign in to watch- Ticker
- ACRS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460571712
- Phone
- 484-324-7933
- Business address
- 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | Balthaser Kevin Chief Financial Officer | Shares withheld for taxes | −313 | $1.24 | $388 | 21,212 |
| 2024-03-01 | Balthaser Kevin Chief Financial Officer | Option exercise | +2,375 | 23,587 | ||
| 2024-03-01 | Balthaser Kevin Chief Financial Officer | Shares withheld for taxes | −677 | $1.24 | $839 | 22,910 |
| 2024-03-01 | Balthaser Kevin Chief Financial Officer | Option exercise · Restricted Stock Units | −1,100 | 1,100 | ||
| 2024-03-01 | Balthaser Kevin Chief Financial Officer | Option exercise · Restricted Stock Units | −2,375 | 4,750 | ||
| 2024-03-01 | Powell Andrew Kenneth William Director | Purchase | +8,500 | $1.23 | $10K | 22,863 |
| 2024-02-01 | Walker Neal Interim CEO | Grant or award · Stock Option (Right to Buy) | +497,000 | 497,000 | ||
| 2024-02-01 | Walker Neal Interim CEO | Grant or award · Restricted Stock Units | +142,000 | 142,000 | ||
| 2024-02-01 | Monahan Joseph Chief Scientific Officer | Option exercise | +7,500 | 137,224 | ||
| 2024-02-01 | Monahan Joseph Chief Scientific Officer | Shares withheld for taxes | −2,583 | $1.20 | $3K | 134,641 |
| 2024-02-01 | Monahan Joseph Chief Scientific Officer | Option exercise · Restricted Stock Unit | −7,500 | 22,500 | ||
| 2024-02-01 | Monahan Joseph Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) | +206,500 | 206,500 | ||
| 2024-02-01 | Monahan Joseph Chief Scientific Officer | Grant or award · Restricted Stock Units | +59,000 | 59,000 | ||
| 2024-02-01 | Monahan Joseph Chief Scientific Officer | Grant or award · Restricted Stock Units | +147,500 | 147,500 | ||
| 2024-02-01 | Loerop James Chief Business Officer | Option exercise | +11,250 | 32,938 | ||
| 2024-02-01 | Loerop James Chief Business Officer | Shares withheld for taxes | −3,853 | $1.20 | $5K | 29,085 |
| 2024-02-01 | Loerop James Chief Business Officer | Option exercise | +7,500 | 36,585 | ||
| 2024-02-01 | Loerop James Chief Business Officer | Shares withheld for taxes | −2,568 | $1.20 | $3K | 34,017 |
| 2024-02-01 | Loerop James Chief Business Officer | Option exercise · Restricted Stock Units | −11,250 | 22,500 | ||
| 2024-02-01 | Loerop James Chief Business Officer | Option exercise · Restricted Stock Unit | −7,500 | 22,500 |
Page 16 of 34 · 680 trades